|
May 12
|
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
|
|
Apr 14
|
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)
|
|
Apr 9
|
MaaT Pharma reports safety interim analysis from trial of microbiome therapy
|
|
Apr 8
|
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
|
|
Apr 7
|
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
|
|
Apr 4
|
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
|
|
Mar 11
|
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
|